AsiaTIDES: Oligonucleotides & Peptide Therapeutics
Tuesday, February 26th – Thursday, February 28th

Hilton Tokyo Bay Hotel
1-8 Maihama, Urayasu-Shi, Chiba Prefecture 279-0031
Tokyo, Japan

EpiVax is sure to cause PANDAmonium in Japan! Come network with us from Tuesday, February 26th through Thursday, February 28th at AsiaTIDES, and learn about our latest immunogenicity screening technology, PANDA (Peptide Abbreviated New Drug Application).


Current FDA guidelines on synthetic peptide drugs mandate that pharmaceutical manufacturers of generic drugs provide information regarding potential impurities in the drug formulation. Using PANDA, individuals can assess the immunogenicity of Reference Listed Drugs, corresponding synthetically-produced generic peptide products and their process-related peptide impurities to evaluate bioequivalence. The PANDA approach is used by many clients for immunogenicity screening in the context of seeking FDA approval for generic peptide products.

To learn more about our PANDA Screening technology, click here.


AsiaTIDES is the only event in Asia that brings together science, technologies, and partners to accelerate oligonucleotide and peptide molecules to market. Connect with 250+ oligonucleotide and peptide leaders across Asia, Europe and North America during networking lunches, dinners and cocktail receptions.

  • Assess the science, technologies and partners you need to grow your business
  • Hear case studies, best practices and lessons learned from global developers
  • Improve your process development, analytical and manufacturing efforts
  • View peer-submitted posters that contain new and unpublished research

For more information and/or to register, please visit AsiaTIDES’ official event page.